drugset / Trial / NCT00975091

Continue Entecavir Rollover From China

NCT00975091

Phase 3 Completed 600 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if treatment with entecavir is safe and well tolerated in patients who completed dosing in a previous entecavir study in China, but are requiring further treatment of their chronic hepatitis B virus infection.

Timeline

Start
2004-05
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entecavir Small molecule 0.5 mg Oral
Comparator Entecavir Small molecule 1 mg Oral